Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

Labbé, Catherine; Anderson, Michaela R.; Simard, Serge; Tremblay, Lise; Laberge, Francis; Vaillancourt, Richard; Lacasse, Yves

doi:10.3747/co.24.3655

Cited by 24 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rapid LC diagnostic units have proven to be very useful, although audits are necessary to evaluate them. 11,26,[30][31][32] In some series, a specific rapid diagnosis program has reduced the delay from 128 to 20 days for the entire management process and significantly reduced the delays to access a specialist or undergo a scan, a bronchoscopy, or PET-CT. 17 Nurse navigation has also improved the time from suspicion of LC to treatment with a trend toward diagnosing non-small cell lung cancer at an earlier stage, both in our study and in previous series. 33 Based on our results, we suggest some areas for improvement.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predicting delays in lung cancer diagnosis and staging

et al. 2019

View full text Add to dashboard Cite

BackgroundDespite growing interest in increasing the efficiency and speed of the diagnosis, staging, and treatment of lung cancer (LC), the interval from signs and symptoms to diagnosis and treatment remains longer than recommended. The aim of this study was to analyze the factors that cause delays in the LC diagnosis/staging process and, consequently, delays in making therapeutic decisions.MethodsWe analyzed audit data from a prospective dataset of 1330 patients assessed at The Lung Cancer Rapid Diagnostic Unit from 26 June 2013 to 26 March 2016. The number and type of procedures and medical tests and the times of all procedures were recorded. Clinical and epidemiological variables and whether the diagnosis was performed on an inpatient or outpatient basis were also recorded.ResultsMalignancy was confirmed in 737 (55.4%) of the 1330 patients, with LC in 627 of these (85.2%). The mean interval to final diagnosis was 19.8 ± 13.9 days. Variables significantly related to a longer diagnostic time were the number of days until computed tomography (CT) was performed (odds ratio [OR], 95% confidence interval [CI] 1.347, 1.103–1.645; P = 0.003), until a histology sample was obtained (OR 1.243, 95% CI1.062–1.454; P = 0.007), and the total number of tests performed during the diagnostic and staging process (OR 1.823, 95% CI 1.046–3.177; P = 0.03).ConclusionsA greater number of tests and more days to CT and histology led to longer delay times. Optimization of these factors should reduce delays in the LC diagnosis process.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Rapid LC diagnostic units have proven to be very useful, although audits are necessary to evaluate them . In some series, a specific rapid diagnosis program has reduced the delay from 128 to 20 days for the entire management process and significantly reduced the delays to access a specialist or undergo a scan, a bronchoscopy, or PET‐CT .…”

Section: Discussionmentioning

confidence: 99%

Predicting delays in lung cancer diagnosis and staging

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Lung cancer diagnosis is crucial for reducing morbidity and increasing the quality of life of patients (24,31,32). An early diagnosis of lung cancer may improve the administration of timely anticancer treatments, including surgery, chemoradiotherapy and immunotherapy, for patients with lung cancer, which can further improve the overall survival and progression-free survival (33)(34)(35). Clinically, PET/CT has been widely used for diagnosing human lung cancer and evaluating metastatic lesions (36).…”

Section: Discussionmentioning

confidence: 99%

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

et al. 2019

View full text Add to dashboard Cite

Positron emission tomography-computed tomography (PET/CT) is an efficient method for the diagnosis of various types of human cancer. Studies have demonstrated that Gd 2 O 3-doped carbon-11-choline (GdCho) can be used as a contrast nanoparticle for PET/CT in the diagnosis of patients with lung cancer. The aim of the present study was to evaluate the effect of GdCho-lenvatinib nanoparticles contrast-PET/CT (GdCho-Len-PET) in the diagnosis and treatment planning of a cohort of patients suspected of having lung cancer. The results of the present study demonstrated that GdCho-Len could be used as an efficient PET/CT contrast agent for the diagnosis of patients with lung cancer. GdCho-Len nanoparticles contrast agent exhibited a significantly improved longitudinal relaxivity compared with GdCho. The outcomes of the present study were that GdCho-Len-PET diagnosed 152 patients with lung cancer, whereas GdCho-PET diagnosed 130 patients with lung cancer among the 172 patients. GdCho-Len-PET presented with higher accuracy and sensitivity compared with GdCho-PET in diagnosing patients with lung cancer. All patients were further confirmed via histological analysis. GdCho-Len-PET contributed to the anticancer treatments in 56 out of 62 (90.3%) patients with lung cancer who were candidates for radiation therapy, 52 out of 57 (91.2%) patients with lung cancer undergoing adjuvant radiotherapy, and 13 out of 17 (76.5%) patients with lung cancer undergoing comprehensive therapy. Patients diagnosed using GdCho-Len-PET improved the survival of patients with lung cancer during a 420-day follow up. In conclusion, GdCho-Len-PET increased the diagnostic efficacy and had a significant effect on survival for patients with lung cancer, and may therefore serve as a reliable method for human cancer diagnosis.

show abstract

“…However, there have been mixed results on whether not meeting guideline times has an impact on survival [80]. A recent study at a single centre found that delays in investigation and treatment do not appear to negatively affect clinical outcomes, but added that studies are needed to evaluate whether efficient work-up and treatment influence other important variables, such as quality of life, cost of care and access to therapies [81].Treatment for SCLC must be offered promptly as the disease progresses rapidly. • With emergency presentation being a major problem in lung cancer, there must be pathways to ensure patients are seen in lung cancer units as soon as possible.…”

Section: Care Pathways and Timelinesmentioning

confidence: 99%

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer

et al. 2020

View full text Add to dashboard Cite

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care throughout the patient journey. Lung cancer is the leading cause of cancer mortality and has a wide variation in treatment and outcomes in Europe. It is a major healthcare burden and has complex diagnosis and treatment challenges. Care must only be carried out in lung cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals detailed here. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.

show abstract

Wait Times for Diagnosis and Treatment of Lung Cancer: A Single-Centre Experience

Abstract: Background Multiple clinical practice guidelines recommend rapid evaluation of patients with suspected lung

Cited by 24 publications

References 24 publications

Predicting delays in lung cancer diagnosis and staging

Predicting delays in lung cancer diagnosis and staging

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer

Contact Info

Product

Resources

About